[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):158-161. doi: 10.3760/cma.j.issn.0253-2727.2023.02.014.
[Article in Chinese]
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bendamustine Hydrochloride / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Lymphoma, B-Cell*
  • Protein Kinase Inhibitors / therapeutic use
  • Rituximab / therapeutic use
  • Treatment Outcome

Substances

  • Rituximab
  • Bendamustine Hydrochloride
  • Protein Kinase Inhibitors

Grants and funding

基金项目：国家自然科学基金（81900167、82170166、81970146）；江苏省人民医院青年拔尖人才专项基金（YNRCQN035）；江苏省自然青年科学基金（BK20191060）